|
1.
|
学術雑誌(原著)
|
DNA microarray gene expression profile of T cells with splice variants of TCRz mRNA observed in SLE. 2006/01
|
|
2.
|
学術雑誌(原著)
|
Critical role of the 5th domain of E-cadherin for heterophilic adhesion with aEb7, but not for homophilic adhesion. 2005/04
|
|
3.
|
学術雑誌(総説)
|
Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: One-year clinical and radiographic outcomes (RECONFIRM-II). 2008/04
|
|
4.
|
学術雑誌(原著)
|
A splice variant of the TCRz mRNA lacking exon7 leads to the downregulation of the TCRz , TCR/CD3 complex and IL-2 production in systemic lupus erythematosus T cells. 2005/04
|
|
5.
|
学術雑誌(原著)
|
Forced expression of TCRζ mRNA with alternatively spliced 3' untranslated region found in SLE patients lead to decreased production and cell surface expresson of TCRζ and TCR-CD3 complex. 2003/06
|
|
6.
|
学術雑誌(原著)
|
Treatment of Rheumatoid Arthritis with humanized anti-IL-6 receptor monoclonal antibody: A muticenter, double-blind, placebo-controlled trial. 2004/06
|
|
7.
|
学術雑誌(原著)
|
T cell abnormalities in systemic lupus erythematosus. 2005/04
|
|
8.
|
学術雑誌(原著)
|
Imatinib mesylate inhibits proliferation of rheumatoid synovial fibloblast-like cells and phosphorylation of Gab adaptor proteins activated by platelet-derived growth factor. 2006/06
|
|
9.
|
学術雑誌(原著)
|
Altered expression of the T cell receptor-CD3 complex in systemic lupus erythematosus 2004/05
|
|
10.
|
学術雑誌(原著)
|
A multi-center, double-blind, placebo-controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis.J Rheum 2006/06
|
|
11.
|
学術雑誌(原著)
|
Aberrant expression of BAFF in T cells of systemic lupus erythematosus, which is recapitulated by a human T cell line, Loucy.Int Immunol 2006/07
|
|
12.
|
学術雑誌(原著)
|
Combination therapy with corticosteroids, cyclosporine A and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. 2005/04
|
|
13.
|
学術雑誌(原著)
|
TCRz mRNA splice variant forms observed in peripheral blood T cells from systemic lupus erythematosus patients.Springer Seminars in Immunopathology 2006/10
|
|
14.
|
学術雑誌(原著)
|
Incidence of cytomegalovirus reactivation in patients with inflammatory connective tissue disease who are in immunosuppressive therapy. 2004/02
|
|
15.
|
学術雑誌(原著)
|
Recent advances in the treatment of interstitial lung disease in patients with polymyositis/dermatomyositis. 2006/12
|
|
16.
|
学術雑誌(原著)
|
Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab.Mod Rheum 2006/12
|
|
17.
|
学術雑誌(原著)
|
Therapeutic targets of misguided T cells in systemic lupus erythematosus. 2005/04
|
|
18.
|
学術雑誌(原著)
|
Lymphoproliferative disorders in rheumatoid arthritis: cliinicopathological analysis of 76 cases in relation to methotrexate medication. J. Rheumatology 2007/02
|
|
19.
|
学術雑誌(原著)
|
Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in rheumatoid arthritis management group in Japan (RECONFIRM).Mod Rheum 2007/02
|
|
20.
|
学術雑誌(原著)
|
Lymphomatoid granulomatosis and diffuse alvelolar damage associated with methotrexate in a patient with rheumatoid arthritis. 2007/09
|
|
21.
|
学術雑誌(原著)
|
Guidelines for the proper use of etanercept in Japan.Mod Rheum 2006/05
|
|
22.
|
学術雑誌(総説)
|
Impact of TNF inhibitors on Rheumatoid Arthritis. 2006/05
|
|
23.
|
学術雑誌(原著)
|
Efficacy and safety of busillamine, a D-Penicillamine analogue, in patients with active Rheumatoid Arthritis.Mod Rheum 2006/04
|
|
24.
|
学術雑誌(原著)
|
Official Japanese guidelines for the use of infliximab for rheumatoid arthritis. 2005/04
|
|
25.
|
学術雑誌(原著)
|
Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients 2004/09
|
|
26.
|
学術雑誌(原著)
|
Anti-TNF biological agents in rheumatoid arthritis and other inflammatory diseases. 2005/04
|
|
27.
|
学術雑誌(原著)
|
Baricitinib dose reduction in patients with rheumatoid arthritis achieving sustained disease control: Final results from the RA-BEYOND study 2025/01/15
|
|
28.
|
学術雑誌(原著)
|
Association of lupus low disease activity State and remission with reduced organ damage and flare in SLE patients with high disease activity 2024/12/04
|
|
29.
|
学術雑誌(原著)
|
Interleukin-17A is a potential therapeutic target predicted by proteomics for systemic sclerosis patients at high risk of pulmonary arterial hypertension 2024/11/27
|
|
30.
|
学術雑誌(原著)
|
The uncoupling of disease activity from joint structural progression in patients with rheumatoid arthritis treated with filgotinib 2024/11/26
|
|
31.
|
学術雑誌(総説)
|
Targeting the Type I IFN Pathway in Glomerular Kidney Disease: Rationale and Therapeutic Opportunities 2024/10/21
|
|
32.
|
学術雑誌(原著)
|
Long-read sequencing of 29 immune cell subsets reveals disease-linked isoforms 2024/03/28
|
|
33.
|
学術雑誌(原著)
|
Prognostic improvement and treatment of COVID-19 in patients with rheumatic diseases until December 2022: analysis of the JCR COVID-19registry in Japan. 2024/03/28
|
|
34.
|
学術雑誌(原著)
|
Tocilizumab discontinuation after remission achievement in patients with adult-onset Still’s disease 2024/03/20
|
|
35.
|
学術雑誌(原著)
|
Cytotoxic Tph subset with low B-cell helper functions and its involvement in systemic lupus erythematosus. 2024/03/06
|
|
36.
|
学術雑誌(原著)
|
Immunosuppressive therapy and humoral response to third mRNA COVID-19 vaccination with a six-month interval in rheumatic disease patients. 2024/03/01
|
|
37.
|
学術雑誌(総説)
|
New generation anti-TNFα agents: example of ozoralizumab 2024/03
|
|
38.
|
学術雑誌(原著)
|
Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Interim-analysis of surveillance 2024/02/26
|
|
39.
|
学術雑誌(原著)
|
SMART-SLE: serology monitoring and repeat testing in systemic lupus erythematosus-an analysis of anti-double-strand DNA monitoring. 2024/02/01
|
|
40.
|
学術雑誌(原著)
|
Malignancy in the upadacitinib clinical trials for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis 2024/02
|
|
41.
|
学術雑誌(原著)
|
Long-term evaluation of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs 2024/01/23
|
|
42.
|
学術雑誌(原著)
|
Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: Results of a long-term study. 2024/01/22
|
|
43.
|
学術雑誌(原著)
|
Long-term safety and effectiveness of tacrolimus in patients with lupus nephritis: 10-year analysis of the real-world TRUST study. 2024/01/01
|
|
44.
|
学術雑誌(原著)
|
Long-term evaluation of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to methotrexate 2023/12/22
|
|
45.
|
学術雑誌(原著)
|
Safety and effectiveness of peficitinib 100 mg/day in patients achieving clinical remission from a long-term open-label extension study in Japan, Korea, and Taiwan (RAJ2). 2023/12/07
|
|
46.
|
学術雑誌(原著)
|
Malignancy in the upadacitinib clinical trials for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. 2023/11/20
|
|
47.
|
学術雑誌(総説)
|
25 years of biologic DMARDs in rheumatology 2023/11/02
|
|
48.
|
学術雑誌(原著)
|
Population Pharmacokinetics of ozoralizumab in patients with rheumatoid arthritis. 2023/11/01
|
|
49.
|
学術雑誌(原著)
|
Association between matrix metalloprotease-3 levels and radiographic progression in patients with RA: a post hoc analysis from a Japanese phase 3 clinical trial of peficitinib (RAJ4) 2023/10/31
|
|
50.
|
学術雑誌(原著)
|
Effect of extended dosing interval of anti-TNF-alpha NANOBODY® compound ozoralizumab in patients with low disease activity rheumatoid arthritis. 2023/10/31
|
|
51.
|
学術雑誌(原著)
|
Nation-wide Cohort Study of Remission Induction Therapy using Rituximab in Japanese patients with ANCA-Associated Vasculitis: effectiveness and safety in the first six months 2023/10/08
|
|
52.
|
学術雑誌(原著)
|
Effect of JAK inhibitors on the three forms of bone damage in autoimmune arthritis: joint erosion, periarticular osteopenia, and systemic osteoporosis. 2023/09/19
|
|
53.
|
学術雑誌(原著)
|
Post hoc analysis of patients with rheumatoid arthritis under clinical remission in two Japanese Phase 3 trials of peficitinib treatment (RAJ3&RAJ4). 2023/06/15
|
|
54.
|
学術雑誌(原著)
|
Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patents with rheumatoid arthritis: Post-hoc analysis of clinical trials 2023/05/17
|
|
55.
|
学術雑誌(原著)
|
Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials. 2023/04/13
|
|
56.
|
学術雑誌(原著)
|
Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4) 2023
|
|
57.
|
学術雑誌(原著)
|
The Efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis 2023
|
|
58.
|
学術雑誌(原著)
|
Clinical and immunological effects of hydroxychloroquine in patients with active arthritis despite anti-rheumatic treatment 2022/12/09
|
|
59.
|
学術雑誌(原著)
|
Associations between the patterns of large-vessel lesions and treatment outcomes in patients with large-vessel giant cell arteritis 2022/10/11
|
|
60.
|
学術雑誌(原著)
|
A pooled analysis of severe infections and herpes zoster-related disease in Asian patients with rheumatoid arthritistreated with peficitinib (ASP015K) over a median of 3 years 2022
|
|
61.
|
学術雑誌(総説)
|
A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs. 2022
|
|
62.
|
学術雑誌(原著)
|
Association of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study 2022
|
|
63.
|
学術雑誌(原著)
|
Association of lupus low disease activity state and remission attainment and reduced mortality in systemic lupus erythematosus: A prospective multi-national, longitudinal cohort study 2022
|
|
64.
|
学術雑誌(原著)
|
Association of methotrexate use and lymphoproliferative disorder in patients with rheumatoid arthritis: results from a Japanese multi-institutional retrospective study 2022
|
|
65.
|
学術雑誌(総説)
|
Cytokines and cytokine receptors as targets of immune-mediated inflammatory diseases- RA as a role model. 2022
|
|
66.
|
学術雑誌(原著)
|
Disease specific expansion of CD29+IL-17RA+ T effector cells possessing multiple signaling pathways in spondyloarthritis. 2022
|
|
67.
|
学術雑誌(原著)
|
Efficacy and safety of abatacept in biologic-naïve patients with active rheumatoid arthritis by background methotrexate dose: Post-hoc analysis of a randomized, placebo-controlled, phase-4 study 2022
|
|
68.
|
学術雑誌(原著)
|
Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prier exposure to methotrexate: Subpopulation analyses of a global phase 3 study (FINCH 3) 2022
|
|
69.
|
学術雑誌(原著)
|
Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: subgroup analyses of a global phase 3 study (FINCH 2) 2022
|
|
70.
|
学術雑誌(原著)
|
IgG4-related disease and idiopathic multicentric Castleman’s disease: confusable immune-mediated disorders 2022
|
|
71.
|
学術雑誌(原著)
|
Immune evasion and chronological decrease in titer of neutralizing antibody against SARS-CoV-2 and its variants of concerns in COVID-19 patients 2022
|
|
72.
|
学術雑誌(原著)
|
Impact of age on the of efficacy and safety of peficitinib for the treatment of rheumatoid arthritis 2022
|
|
73.
|
学術雑誌(原著)
|
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years 2022
|
|
74.
|
学術雑誌(原著)
|
Interleukin-4 as an emerging therapeutic target for IgG4-related disease 2022
|
|
75.
|
学術雑誌(総説)
|
Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still’s disease 2022
|
|
76.
|
学術雑誌(総説)
|
Longitudinal monitoring of circulating immune cell phenotypes in large vessel vasculitis 2022
|
|
77.
|
学術雑誌(原著)
|
Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus 2022
|
|
78.
|
学術雑誌(原著)
|
Novel susceptibility loci for steroid-associated osteonecrosis of the femoral head in systemic lupus erythematosus 2022
|
|
79.
|
学術雑誌(原著)
|
Phase II/III results of the anti-TNF multivalent NANOBODY® compound ‘ozoralizumab’ in patient with rheumatoid arthritis (OHZORA trial) 2022
|
|
80.
|
学術雑誌(原著)
|
Potent neutralizing broad-spectrum antibody against SARS-CoV-2 generated from double-antigen-specific B cells from convalescents 2022
|
|
81.
|
学術雑誌(原著)
|
Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics 2022
|
|
82.
|
学術雑誌(原著)
|
Rheumatoid arthritis with nontuberculous mycobacterial pulmonary disease: A retrospective, single center-cohort study 2022
|
|
83.
|
学術雑誌(原著)
|
Role of interferons (IFNs) in differentiation of T peripheral helper cells (Tph) cells. 1: Type 1 IFNs promote differentiation of interleukin-21-producing Tph-like cells 2022
|
|
84.
|
学術雑誌(原著)
|
Role of interferons (IFNs) in differentiation of T peripheral helper cells (Tph) cells. 2: IFNαand IFNλcooperatively contribute to the expansion of Tph cells in systemic lupus erythematosus 2022
|
|
85.
|
学術雑誌(原著)
|
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: Final results from long-term extension study and integrated database 2022
|
|
86.
|
学術雑誌(原著)
|
Should we consider the definition of elderly-onset rheumatoid arthritis in an aging society? 2022
|
|
87.
|
学術雑誌(総説)
|
T follicular helper cells mediate local production of allergen-specific IgE and IgG4 2022
|
|
88.
|
学術雑誌(原著)
|
The long-term safety and effectiveness of mycophenolate mofetil in adults with lupus nephritis: a real-world study in Japan 2022
|
|
89.
|
学術雑誌(原著)
|
‘Not at target’: Prevalence and consequences of inadequate disease control in systemic lupus erythematosus - A multinational observational cohort study 2022
|
|
90.
|
学術雑誌(原著)
|
A phase 2 study of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying anti-rheumatic drugs 2021
|
|
91.
|
学術雑誌(原著)
|
A phase 2a, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral gonadotropin-releasing hormone antagonist, ASP1707, in post-menopausal female patients with rheumatoid arthritis taking methotrexate 2021
|
|
92.
|
学術雑誌(原著)
|
A pooled safety analysis of peficitinib (ASP015K) Asian patients with rheumatoid arthritis treated over a median of 2 years 2021
|
|
93.
|
学術雑誌(総説)
|
An update on the pathogenic role of IL-6 in rheumatic diseases 2021
|
|
94.
|
学術雑誌(原著)
|
Anti-centromere antibodies target centromere-kinetochore macrocomplex: a comprehensive autoantigen profiling 2021
|
|
95.
|
学術雑誌(原著)
|
Antigen-driven autoantibody production in lungs of interstitial lung disease with autoimmune disease 2021
|
|
96.
|
学術雑誌(原著)
|
Association between mortality and cytomegalovirus reactivation during remission induction therapy in patients with rheumatic diseases 2021
|
|
97.
|
学術雑誌(総説)
|
Characteristics and prognosis of IgG4-related skin disease: a case report and systematic literature review 2021
|
|
98.
|
学術雑誌(原著)
|
Characteristics of patients with difficult-to-treat rheumatoid arthritis in real-world 2021
|
|
99.
|
学術雑誌(原著)
|
COVID-19 shares clinical features with anti-melanoma differentiation associated protein 5 positive dermatomyositis and adult Still’s disease 2021
|
|
100.
|
学術雑誌(原著)
|
Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL-Strategy 2021
|
|
101.
|
学術雑誌(原著)
|
Distinct expression of coinhibitory molecules on alveolar T cells in patients with rheumatoid arthritis- and idiopathic inflammatory myopathies-associated interstitial lung disease 2021
|
|
102.
|
学術雑誌(原著)
|
Distinct features between HLA-DR+ and HLA-DR- PD-1hi CXCR5- T peripheral helper cells in seropositive rheumatoid arthritis 2021
|
|
103.
|
学術雑誌(原著)
|
Early combination of pulmonary vasodilators prevents chronic kidney disease progression in connective tissue disease-associated pulmonary hypertension 2021
|
|
104.
|
学術雑誌(原著)
|
Effects of denosumab in Japanese patients with rheumatoid arthritis treated with conventional anti-rheumatic drugs:36-month extension of a phase III study 2021
|
|
105.
|
学術雑誌(原著)
|
Efficacy and safety of abatacept in active primary Sjogren’s syndrome: results fo a phase III, randomized, placebo-controlled trial 2021
|
|
106.
|
学術雑誌(原著)
|
Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis with Inadequate Response to Methotrexate 2021
|
|
107.
|
学術雑誌(原著)
|
Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE) 2021
|
|
108.
|
学術雑誌(原著)
|
Elderly patients with comorbidities in the definition of difficult-to-treat rheumatoid arthritis 2021
|
|
109.
|
学術雑誌(原著)
|
Exacerbation of immune thrombocytopenia triggered by COVID-19 infection in patients with systemic lupus erythematosus 2021
|
|
110.
|
学術雑誌(原著)
|
Incomplete humoral response including neutralizing antibodies in asymptomatic and mild COVID-19 patients in Japan 2021
|
|
111.
|
学術雑誌(原著)
|
Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study 2021
|
|
112.
|
学術雑誌(原著)
|
Is type 2 diabetes mellitus an inverse risk factor for the development of rheumatoid arthritis? 2021
|
|
113.
|
学術雑誌(原著)
|
Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies 2021
|
|
114.
|
学術雑誌(原著)
|
Long-term Safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomized controlled trials (SIRROUND-LTE) 2021
|
|
115.
|
学術雑誌(原著)
|
Lymphoadenopathy in IgG4-related disease: a phenotype of severe activity and poor prognosis, with eotaxin-3 as a new biomarker 2021
|
|
116.
|
学術雑誌(原著)
|
Milk fat globule epidermal growth factor 8 (MFG-E8) on monocytes is a novel biomarker of disease activity in systemic lupus erythematosus 2021
|
|
117.
|
学術雑誌(原著)
|
Molecular remission at T cell level in patients with rheumatoid arthritis 2021
|
|
118.
|
学術雑誌(原著)
|
Patient- and physician-reported outcomes from two Phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis 2021
|
|
119.
|
学術雑誌(原著)
|
Peripheral TIGIT+ T follicular helper cells that produce high levels of interleukin-21 via OX40 represent disease activity of IgG4-related diseases 2021
|
|
120.
|
学術雑誌(原著)
|
Platelet CXCL4 mediates neutrophil extracellular traps formation in ANCA-associated vasculitis 2021
|
|
121.
|
学術雑誌(原著)
|
Points to consider for the treatment of immune mediated inflammatory diseases with Janus kinase inhibitors- A consensus statement. 2021
|
|
122.
|
学術雑誌(原著)
|
Predictors of new bone erosion inrheumatoid arthritis patients receiving conventional synthetic anti-rheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies 2021
|
|
123.
|
学術雑誌(原著)
|
Proton pump inhibitor and tacrolimus use is associated with hypomagnesemia in connective tissue disease: a potential pathogenic link with renal deterioration and recurrent infection 2021
|
|
124.
|
学術雑誌(原著)
|
Radiographic and clinical effects of 10mg and 25mg twice-weekly etanercept over 52 weeks in Japanese patients with active rheumatoid arthritis 2021
|
|
125.
|
学術雑誌(総説)
|
Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: a systemic literature review 2021
|
|
126.
|
学術雑誌(総説)
|
Role of Interleukin-6 in bone destruction and bone repair in rheumatoid arthritis 2021
|
|
127.
|
学術雑誌(原著)
|
Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: final results (32 months of mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan 2021
|
|
128.
|
学術雑誌(原著)
|
Safety and tolerability of ultrasound-guided synovial needle biopsy in Japanese arthritis patients 2021
|
|
129.
|
学術雑誌(原著)
|
Steroid-sparing effect of tocilizumab and methotrexate in patients with polymyalgia rheumatica : a retrospective cohort study 2021
|
|
130.
|
学術雑誌(原著)
|
Successful treatment of anti-MDA5 antibody-positive dermatomyositis-associated rapidly progressive-interstitial lung disease by plasma exchange: Two case reports 2021
|
|
131.
|
学術雑誌(原著)
|
The Interleukin-1 pathway in active large vessel vasculitis patients with a poor prognosis: a longitudinal transcriptome analysis 2021
|
|
132.
|
学術雑誌(原著)
|
The safety profile of upadacitinib in patients with rheumatoid arthritis in Japan 2021
|
|
133.
|
学術雑誌(原著)
|
Thymus variants on imaging in patients with rheumatoid arthritis- clinical and immunological significance 2021
|
|
134.
|
学術雑誌(原著)
|
Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: a literature review 2021
|
|
135.
|
学術雑誌(原著)
|
Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: A sub-analysis of the Phase 3 SELECT-EARLY study 2021
|
|
136.
|
学術雑誌(総説)
|
Monitoring of cDNA microarray profile in peripheral blood during infliximab treatment of Rheumatoid Arthritis patients 2008/04
|
|
137.
|
学術雑誌(総説)
|
Post-marketing Surveillance of the Safety Profile of Infliximab in 5,000 Japanese Patients with Rheumatoid Arthritis. 2008/03
|
|
138.
|
学術雑誌(総説)
|
Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: One-year clinical and radiographic outcomes (RECONFIRM-II). 2007/12
|
|
139.
|
学術雑誌(総説)
|
Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. 2007/12
|
|
140.
|
学術雑誌(総説)
|
Platelet-Derived Growth Factor as a Therapeutic Target for systemic autoimmune diseases. 2007/09
|
|
141.
|
学術雑誌(総説)
|
クラスター分類の最新の情報 2007/09
|
|
142.
|
学術雑誌(総説)
|
The SAMURAI Study:Study of Active Controlled Monotherapy Used for Rheumatoid Arthritis, an IL-6 inhibitor - Evidence of clinical and radiographic benefit from an X-Ray Reader-Blinded Randomized Controlled Trial of Tocilizumab. 2007/07
|
|
143.
|
学術雑誌(総説)
|
Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in rheumatoid arthritis management group in Japan (RECONFIRM) 2007/06
|
|
144.
|
学術雑誌(総説)
|
CLTA-4ヒトIG融合蛋白 abatacept 2007/05
|
|
145.
|
学術雑誌(総説)
|
Lymphomatoid granulomatosis and diffuse alvelolar damage associated with methotrexate in a patient with rheumatoid arthritis. 2007/05
|
|
146.
|
学術雑誌(総説)
|
特集：新しい生物学的製剤 序 2007/05
|
|
147.
|
学術雑誌(総説)
|
エタネルセプト（エンブレルR）による炎症性疾患の制御 2007/03
|
|
148.
|
学術雑誌(原著)
|
リウマチ薬物治療の現状および問題点 2007/03
|
|
149.
|
学術雑誌(総説)
|
認知症と膠原病 2007/02
|
|
150.
|
学術雑誌(総説)
|
関節リウマチ診療の進歩 2007/02
|
|
151.
|
学術雑誌(総説)
|
インフリキシマブの安全性—感染症リスクを中心としてー 2007/01
|
|
152.
|
学術雑誌(総説)
|
膠原病治療における生物学的製剤の光と影 2007/01
|
|
153.
|
学術雑誌(総説)
|
エタネルセプト：使い方と市販後調査 2006/12
|
|
154.
|
学術雑誌(その他)
|
関節リウマチに対する積極的治療の意義：治療目標としての［寛解］ 2006/10
|
|
155.
|
学術雑誌(総説)
|
合併症妊娠の予後』自己免疫疾患合併妊娠 自己免疫疾患専門医. 2006/09
|
|
156.
|
学術雑誌(総説)
|
関節リウマチに対する薬物療法〜基本的考え方とその実践方法〜 2006/09
|
|
157.
|
学術雑誌(総説)
|
関節リウマチの疼痛管理 2006/08
|
|
158.
|
学術雑誌(総説)
|
関節リウマチ治療におけるタクロリムス血中濃度測定の臨床的意義と今後の課題 2006/08
|
|
159.
|
学術雑誌(総説)
|
In vitro TNF産生能によるインフリキシマブ有効性の予測 2006/06
|
|
160.
|
学術雑誌(総説)
|
どのような症例に生物学的製材を使用すべきか 2006/05
|
|
161.
|
学術雑誌(総説)
|
インフリキシマブ 2006/05
|
|
162.
|
学術雑誌(総説)
|
特集：自己免疫疾患の新しい治療法-生物学的製剤を中心に- インフリキシマブ 2006/05
|
|
163.
|
学術雑誌(総説)
|
疾患修飾性抗リウマチ薬 (DMARD) (3)生物学的製剤 (TNF阻害薬) インフリキシマブ 2006/05
|
|
164.
|
学術雑誌(総説)
|
関節リウマチに対する新しい薬物療法 2006/04
|
|
165.
|
学術雑誌(総説)
|
関節リウマチ治療の実際と新たな展開 2006/04
|
|
166.
|
学術雑誌(総説)
|
マイクロアレイ解析の現状とその将来に期待される展開 2006/03
|
|
167.
|
学術雑誌(総説)
|
関節評価の実際と課題 2006/03
|
|
168.
|
学術雑誌(総説)
|
マイクロアレイ解析の現状とその将来に期待される展開 2006/02
|
|
169.
|
学術雑誌(総説)
|
リウマチ患者の骨粗しょう症治療 2006/02
|
|
170.
|
学術雑誌(総説)
|
抗リウマチ薬による間質性肺炎、結核 2006/02
|
|
171.
|
学術雑誌(総説)
|
抗リウマチ薬の薬剤性肺障害 2006/02
|
|
172.
|
学術雑誌(その他)
|
関節リウマチにおける関節組織破壊のしくみ（眼で見る免疫疾患のしくみ） 2006/02
|
|
173.
|
学術雑誌(総説)
|
RA最新の薬物治療 2006/01
|
|
174.
|
学術雑誌(総説)
|
抗リウマチ薬 タクロリムス水和物 プログラフカプセル 2006/01
|
|
175.
|
学術雑誌(総説)
|
生物学的製剤による関節リウマチの関節破壊抑制 2005/11
|
|
176.
|
学術雑誌(総説)
|
RA治療を帰る生物学的製剤?その期待と課題? 2005/10
|
|
177.
|
学術雑誌(その他)
|
ステロイド性骨粗しょう症の予防と治療 2005/09
|
|
178.
|
学術雑誌(総説)
|
関節リウマチ早期例と生物学的製剤 2005/09
|
|
179.
|
学術雑誌(原著)
|
関節リウマチ患者における血清マトリックスメタロプロテイナーゼ-3 (MMP-3) の臨床的意義 2005/07
|
|
180.
|
学術雑誌(総説)
|
抗TNF-α抗体 2005/05
|
|
181.
|
学術雑誌(総説)
|
関節リウマチ(RA) 2005/05
|
|
182.
|
学術雑誌(総説)
|
Felty症候群 2005/04
|
|
183.
|
学術雑誌(その他)
|
TNF αtargeting therapy: History, present and future strategies: 2005/04
|
|
184.
|
学術雑誌(総説)
|
【高齢者にみられるリウマチ性疾患の診断と治療】 リウマチ性多発筋痛症・側頭動脈炎 2005/04
|
|
185.
|
学術雑誌(総説)
|
わが国の生物学的製剤使用のためのガイドライン 2005/04
|
|
186.
|
学術雑誌(総説)
|
インフリキシマブと肺炎 2005/04
|
|
187.
|
学術雑誌(総説)
|
インフリキシマブによる肺炎の発生状況 2005/04
|
|
188.
|
学術雑誌(総説)
|
インフリキシマブ全例市販後調査の概要 2005/04
|
|
189.
|
学術雑誌(総説)
|
全身性エリテマトーデスと血栓 2005/04
|
|
190.
|
学術雑誌(総説)
|
抗サイトカイン療法の実際と今後の課題 2005/04
|
|
191.
|
学術雑誌(その他)
|
最新のRA薬物療法?座談会? 2005/04
|
|
192.
|
学術雑誌(その他)
|
最近のRA薬物療法 2005/04
|
|
193.
|
学術雑誌(総説)
|
炎症性サイトカインを標的とした生物学的製剤 2005/04
|
|
194.
|
学術雑誌(総説)
|
生物学的製剤、免疫抑制薬 2005/04
|
|
195.
|
学術雑誌(総説)
|
生物学的製剤による炎症性疾患治療の新ステージ 2005/04
|
|
196.
|
学術雑誌(総説)
|
生物学的製剤のPMS後の臨床?序? 2005/04
|
|
197.
|
学術雑誌(総説)
|
生物学的製剤の現状 2005/04
|
|
198.
|
学術雑誌(総説)
|
生物学的製剤の適応と課題 2005/04
|
|
199.
|
学術雑誌(総説)
|
膠原病の臨床所見とその読み方(d)治療 2005/04
|
|
200.
|
学術雑誌(総説)
|
関節リウマチにおけるTNF?α療法 2005/04
|
|
201.
|
学術雑誌(総説)
|
関節リウマチにおける分子標的治療の有効性と副作用 2005/04
|
|
202.
|
学術雑誌(総説)
|
関節リウマチに対する分子標的療法の個別化 2005/04
|
|
203.
|
学術雑誌(総説)
|
関節リウマチに対する抗TNF療法 2005/04
|
|
204.
|
学術雑誌(総説)
|
関節リウマチの病因と病態 2005/04
|
|
205.
|
学術雑誌(総説)
|
関節リウマチの薬物治療?生物学的製剤による最近の進歩? 2005/04
|
|
206.
|
学術雑誌(症例報告)
|
再発性多発軟骨炎様の臨床症状を呈した顕微鏡的多発血管炎の1例 2005/02
|
|
207.
|
学術雑誌(総説)
|
抗リン脂質抗体症候群の診断における抗ホスファチジルセリン・プロトロンビン複合体抗体測定の臨床的意義−多施設間成績− 2005/02
|
|
208.
|
学術雑誌(総説)
|
関節リウマチに対するTNF阻害療法 2005/02
|
|
209.
|
学術雑誌(総説)
|
生物学的製剤使用のためのガイドライン 2005/01
|
|
210.
|
学術雑誌(総説)
|
生物学的製剤使用のためのガイドライン 関節リウマチー成因研究から治療の新時代へー 2005/01
|
|
211.
|
学術雑誌(総説)
|
薬物療法 生物学的製剤 概説 関節リウマチー成因研究から治療の新時代へー 2005/01
|
|
212.
|
学術雑誌(総説)
|
関節リウマチの網羅的発現解析 2005/01
|
|
213.
|
学術雑誌(総説)
|
TNF阻害療法による関節破壊抑制と破壊修復 2005
|
|
214.
|
学術雑誌(その他)
|
多発性筋炎／皮膚筋炎 2005
|
|
215.
|
学術雑誌(総説)
|
抗リウマチ薬 2005
|
|
216.
|
学術雑誌(総説)
|
生物学的製剤の可能性と限界 2005
|
|
217.
|
学術雑誌(総説)
|
新しい抗リウマチ薬の効果と問題点：3) 生物学的製剤 2004/06
|
|
218.
|
学術雑誌(総説)
|
PD-1と自己免疫 2004
|
|
219.
|
学術雑誌(総説)
|
RAにおける抗サイトカイン療法 2004
|
|
220.
|
学術雑誌(総説)
|
RAに対する生物学的製剤の新薬開発の現状と課題 2004
|
|
221.
|
学術雑誌(総説)
|
RAは治癒できるか？ 2004
|
|
222.
|
学術雑誌(総説)
|
SLE,SLE疑診例におけるループスアンチコアグラント測定の臨床的意義 2004
|
|
223.
|
学術雑誌(総説)
|
SLE発症前の自己抗体 2004
|
|
224.
|
学術雑誌(総説)
|
TNFを標的とした慢性炎症性疾患の治療─抗TNF生物製剤による関節リウマチの寛解導入 2004
|
|
225.
|
学術雑誌(総説)
|
TNF阻害による関節リウマチの治療 2004
|
|
226.
|
学術雑誌(総説)
|
キメラ型抗TNFα抗体による関節リウマチの治療 2004
|
|
227.
|
学術雑誌(総説)
|
リウマチ性疾患 2004
|
|
228.
|
学術雑誌(総説)
|
レルフノミド 2004
|
|
229.
|
学術雑誌(その他)
|
全身性エリテマトーデス，多発性筋炎／皮膚筋炎 2004
|
|
230.
|
学術雑誌(その他)
|
分子生物学からみた炎症 2004
|
|
231.
|
学術雑誌(総説)
|
抗TNF製剤による治療 2004
|
|
232.
|
学術雑誌(総説)
|
新しいリウマチ薬 2004
|
|
233.
|
学術雑誌(総説)
|
新・抗リウマチ薬の登場で治療効果をさらに期待 2004
|
|
234.
|
学術雑誌(総説)
|
早期RAの鑑別診断 2004
|
|
235.
|
学術雑誌(総説)
|
生物学的製剤の新薬開発の現状と問題点 2004
|
|
236.
|
学術雑誌(その他)
|
膠原病肺病変に対するシクロスポリン 2004
|
|
237.
|
学術雑誌(総説)
|
膠原病肺病変に対するシクロスポリン療法 2004
|
|
238.
|
学術雑誌(総説)
|
膠原病関連間質性肺炎の治療 2004
|
|
239.
|
学術雑誌(総説)
|
関節リウマチにおけるT細胞副刺激経路阻害療法 2004
|
|
240.
|
学術雑誌(総説)
|
関節リウマチにおける生物学的製剤による治療 2004
|
|
241.
|
学術雑誌(総説)
|
関節リウマチの大規模臨床試験とエビデンス 2004
|
|
242.
|
学術雑誌(総説)
|
関節リウマチの大規模臨床試験とエビデンス 2004
|
|
243.
|
学術雑誌(総説)
|
関節リウマチの抗TNFα療法〜インフリキシマブ，エタネルセプト，アダリムマブ 2004
|
|
244.
|
学術雑誌(総説)
|
関節リウマチの病態・治療に対する生物学的・分子生物学的アプローチ 2004
|
|
5件表示
|
|
全件表示(244件)
|
